Taburnaemine E






Names

    • Taburnaemine E

Attributes

  • Canonical SMILES

    C/C=C1[C@@]2([H])C[C@@H](C3=C4C(C(CCN([C@@H]5CO)[C@]6([H])[C@@]7(C(OC)=O)C[C@@]5([H])C[C@]6([H])CC)=C7N4)=CC=C3OC)C8=C(C[C@]([C@]2(C(OC)=O)COC9)([H])N9C\1)C%10=C(N8)C=CC=C%10

  • InChI

    InChI=1S/C45H54N4O7/c1-6-24-16-26-19-44(42(51)54-4)40-29(14-15-49(41(24)44)34(26)21-50)28-12-13-35(53-3)37(39(28)47-40)31-17-32-25(7-2)20-48-23-56-22-45(32,43(52)55-5)36(48)18-30-27-10-8-9-11-33(27)46-38(30)31/h7-13,24,26,31-32,34,36,41,46-47,50H,6,14-23H2,1-5H3/b25-7-/t24-,26+,31-,32+,34+,36-,41-,44+,45-/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 129.35
  • #RotBonds: 6
  • MW: 762.948
  • HBD: 3
  • HBA: 9
  • logP: 5.577900000000005
  • Chemical Formula: C45H54N4O7


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. corymbosa Malaysia, China 1679252 GK604

External Databases


References

  • Taburnaemines A-I, Cytotoxic Vobasinyl-Iboga-Type Bisindole Alkaloids from Tabernaemontana corymbosa. J Nat Prod, 2018 (PMID 29319316).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Antiproliferative

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.94
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Non-Absorbed
    Madin-Darby Canine Kidney 203.32
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 27333.04
    Distribution Blood-Brain Barrier (Central Nervous System) -3.1
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.13
    Plasma Protein Binding 81.31
    Steady State Volume of Distribution 4.83
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Inhibitor
    Excretion Clearance 9.72
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Toxic
    Bee Toxic
    Bioconcentration Factor -637.35
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.35
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 4.51
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -49605745.16
    Rat (Acute) 2.92
    Rat (Chronic Oral) 2.13
    Fathead Minnow 62619.56
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Toxic
    SR-p53 Safe
    General Properties Boiling Point 5575220.95
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 5.38
    Log(P) 5.32
    Log S -5.45
    Log(Vapor Pressure) -183505.91
    Melting Point 271.48
    pKa Acid -1281.98
    pKa Basic 9.09